Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or empirical data reported
PubMed 33162935 · doi:10.3389/fendo.2020.573479
What was done
This narrative review examined the relationship between psychotropic medications and the prevalence of obesity and other components of the metabolic syndrome in individuals with serious mental illness, including schizophrenia, bipolar disorder, and major depressive disorder.
What was found
The abstract reports no numerical data, risk estimates, or study counts. It qualitatively notes that individuals with serious mental illness face higher mortality and shortened life expectancy primarily from cardiovascular disease, driven by obesity and metabolic abnormalities, and that psychotropic medications independently increase these metabolic risks beyond lifestyle factors.
Why it matters
It highlights that elevated cardiovascular and metabolic risks in serious mental illness stem not only from lifestyle factors but also from the independent adverse effects of psychotropic pharmacotherapy.
Limits
As presented in the abstract, no quantitative metrics, specific drug class comparisons, search strategy, or sample sizes are provided. As a narrative review, it lacks formal systematic review or meta-analytic synthesis.
Cited by
- supports Many of the mainstream medications for bipolar disorder directly lead to metabolic dysfunction.